 |
|
 |
|
| News |  |
|
|
| Firmen | |
|
|
| Industrieinformationen | |
|
|
| Journale | |
|
|
| Bücher | |
|
|
| Events | |
|
|
| Hotlinks | |
|
|
| Newsletter abonnieren | |
|
|
| Impressum | |
|
|
|
|
|
Celltech Pharma GmbH & Co. KG
Bamler Straße 1B 45141 Essen Tel.: 0201/4373-235
Celltech is a leading European biotechnology company, with a substantial long-term commitment to innovative drug discovery and development. Celltech's extensive product pipeline provides excellent prospects for sustained growth, driving its goal of becoming a global biotechnology leader.
Celltech is pursuing an R&D-centred strategy, with its substantial investment in R&D being sustained by revenues from its profitable and cash-generative pharmaceutical business. The company is focused upon maximising value retention from its products, whilst maintaining an appropriate risk/reward profile. This approach includes partnering for strength with major pharmaceutical companies who excel in a particular disease area, where Celltech retains co-marketing rights, profit-sharing arrangements, or substantial royalties. The Group consists of two operating companies: Celltech R&D, the discovery and development business; and Celltech Pharmaceuticals, the marketing, distribution, and manufacturing business. Celltech R&D is pursuing a dual-pipeline approach, focused in its core areas of autoimmune and inflammatory disorders and cancer. In the therapeutic antibody field, a combination of expertise and innovative technologies enables Celltech to move rapidly from antibody targets to clinical trials of engineered human antibodies. In addition, Celltech has strong capabilities in the design and production of small molecule therapeutics. Celltech Pharmaceuticals is the international pharmaceutical business, with substantial operations in the US and a number of major European countries. The pharmaceutical business will provide a platform for the future commercialisation of Celltech's pipeline products in specialised therapy areas.
[zurück] |
|
|
